Figure 5.

Serglycin-mediated CD44 upregulation by activating the MAPK pathway. (a) CNE2 cells were transiently transfected with serglycin. Serglycin and CD44 mRNA levels were detected by quantitative real-time PCR (left panel). Protein levels of CD44, p-ERK1/2, t-ERK1/2 and GAPDH were determined by western blot analysis (right panel). (b) CNE2 cells were stimulated by serglycin-CM from S18 cells. The change in CNE2 cellular morphology (× 40, left panel). Protein levels of CD44, p-ERK1/2, t-ERK1/2 and GAPDH were evaluated by western blot analysis (right panel). (c) Analysis of CD44 luciferase activity in serglycin knockdown cells (left panel) and serglycin overexpressing cells (right panel). GLuc activities in buffers with a stabilizer. Data represent the average±S.D., n=3; *P<0.05 versus control cells. (d) Number of spheres formed by S18 and S26 cells after treatment with IgG or anti-serglycin antibody. Data represent the average±S.D., n=3; *P<0.05 for S26 cells compared with S18 cells